Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Recipient : Adhera Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Adhera Inks Exclusive License Agreement with Melior Pharmaceuticals for MLR-1023
Details : Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes. MLR-1023, a lyn kinase activator, which has shown exceptional clinical safety and tolerability in Phase 2a and Phase 2b ...
Brand Name : MLR-102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : Tolimidone
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Adhera Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Melior Pharmaceuticals Announces Execution of License Agreement
Details : Melior has uncovered a previously unreported therapeutic potential of MLR-1019 in PD. As such it represents a new class of PD therapeutic which may be the only drug candidate to address both movement and non-movement aspects of PD.
Brand Name : MLR-1019
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 29, 2021
Details : Under the terms of the intended acquisition, Adhera will continue clinical development of MLR-1019 (Armesocarb ). Melior Pharmaceuticals will receive Adhera stock plus royalties.
Brand Name : MLR-1019
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 07, 2021
Lead Product(s) : Tolimidone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic
Details : The planned Phase 2 study is intended to recruit 236 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone will be taken as an orally administered pill once a day.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 09, 2021
Lead Product(s) : Tolimidone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tolimidone
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Commonwealth of Pennsylvania’s COVID-19 Vaccines
Deal Size : Undisclosed
Deal Type : Funding
Details : The Phase 2 clinical trial is intended to test tolimidone in subjects who were recently diagnosed with COVID19, but are not hospitalized. Tolimidone is expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complica...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 15, 2020
Lead Product(s) : Tolimidone
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Commonwealth of Pennsylvania’s COVID-19 Vaccines
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?